New Injection Makes Fat Cells Self-Destruct, Slashing Dangerous Organ Fat by 12%

A Different Kind of Fat Fighter

Not all body fat is created equal. The kind you can pinch at your waist is largely cosmetic. But the fat hiding deep inside your abdomen — wrapping around your liver, intestines, and kidneys — is a different story entirely. This hidden fat is biologically active and can interfere with the body's ability to regulate blood sugar and metabolism, and excess amounts are a major contributor to insulin resistance, type 2 diabetes, and cardiometabolic conditions including heart attacks and strokes. Now, an experimental injection called CBL-514 is showing early but striking results in the fight against it.

Dr. W. Timothy Garvey of the University of Alabama at Birmingham and Yu-Fang Ling of drug developer Caliway Biopharmaceuticals in New Taipei City, Taiwan, examined whether CBL-514 could reduce those deposits — and by analyzing MRI scans from two phase 2 trials, they found that visceral fat decreased in participants receiving the drug while increasing in those given a placebo.

How the Drug Actually Works

The CBL-514 injection selectively sparks apoptosis — a process that causes cells to self-destruct — but only in fat cells, leaving nearby cells unharmed. That selectivity is a key part of what makes this drug so scientifically interesting. Rather than simply shrinking fat cells the way diet and exercise do, CBL-514 eliminates them altogether.

Researchers assessed the drug's efficacy by analyzing a subgroup of 40 participants with available MRI data from two phase 2 trials. Participants were injected with up to 600 mg of CBL-514 or a placebo into the lower abdomen every three weeks for up to 12 weeks, with injection frequency tapered as the abdominal fat thickness decreased. The number of injections given depended on the thickness of each participant's abdominal fat, and as the fat layer decreased in volume, the number of injections also decreased.

The Numbers Behind the Breakthrough

Participants who received CBL-514 lost 12% of their visceral fat four weeks after treatment, compared with a nearly 6% increase in the placebo group. That's not just a reduction — it's a reversal of a trend that was actively worsening in the control group. The drug reduced visceral fat volume by nearly 12% at week 4 and by roughly 10% at weeks 8-12, even as visceral fat volume continued to increase in individuals given a placebo over the same time periods.

Phase 2 trials had already shown that CBL-514 could reduce subcutaneous fat, the layer beneath the skin — with 69.6% of treated participants having lost at least 150 milliliters of that fat, about five U.S. fluid ounces, compared with none of those receiving a placebo. The new visceral fat findings go deeper, literally and medically.

What Comes Next — and Why It Matters

In animal studies, CBL-514 has been shown to reduce visceral fat especially when combined with GLP-1 drugs — the same class of medications behind blockbuster weight-loss treatments like Ozempic and Wegovy. Animal data confirmed that CBL-514 combined with GLP-1-based therapies achieved superior weight loss compared to either treatment alone, and following treatment cessation, weight regain in the monotherapy group was 2.7 times that observed in the CBL-514 combination group — a finding with enormous implications for the millions of people who regain weight after stopping GLP-1 medications.

Larger clinical trials are now underway to assess CBL-514's overall safety and efficacy. If those results hold up, this injection could represent a meaningful new tool — not just for weight loss, but for treating the metabolic conditions that visceral fat quietly drives for years before a diagnosis ever arrives.